Gliknik Website, Blog & Press Pages

Gliknik Website, Blog & Press Pages - aVenture

Gliknik - Library

gliknik.comCrawled Oct 15, 2026

Blog

2 pages

News/news
Gliknik Inc. Raises $11.5 Million in Series C Financing —Read More
News/news/news-2

Careers & Hiring

1 page

Careers/contact-us/careers
Gliknik discovers and develops biologics for individuals with autoimmune diseases.

About

6 pages

About/about
Gliknik is a privately held biopharmaceutical company developing therapies for people with immune disorders. It has two drugs in clinical trials and other candidates in preclinical development.
Board of Directors/about/our-board
The Gliknik Board of Directors has deep industry expertise with a track record for discovering and developing marketed drugs and generating successful exits for investors.
Final Gliknik 2014 DSC_5820 Coyle Studios/about/final-gliknik-2014-dsc_5820-coyle-studios
Leadership team/about/our-leadership-team
The page lists David S. Block as chairman and CEO and Henrik S. Olsen, Ph.D., as vice president of drug discovery. Olsen worked at Human Genome Sciences, Artesian Therapeutics, and Celera before joining Gliknik.

Contact

5 pages

Contact Us/contact-us
The company lists its address as 801 W. Baltimore Street, Suite 501A, Baltimore, MD 21201, and its phone number as (410) 685-0662.
Contact-Gliknik/contact-us/contact-gliknik
DSC_5590 Careers/contact-us/dsc_5590-careers
Gliknik-Careers/contact-us/gliknik-careers

Homepage

1 page

Homepage/

Coverage

7 items

An $11.5M Series C will help Gliknik advance 3 treatments for cancer, autoimmune diseasetechnical.ly/startups/gliknik-series-c/
Gliknik raises an $11.5 million Series C to advance three treatments for cancer and autoimmune disease. The University of Maryland BioPark-based company has raised $81 million in total.
Jun 2021 · Technical.lyNews article
Gliknik receives $15M payment from Pfizer after reaching clinical milestonetechnical.ly/startups/gliknik-receives-15m-payment-from-pfizer-after-reaching-clinical-milestone/
Gliknik receives a $15 million payment from Pfizer after its drug candidate reaches a clinical milestone. The University of Maryland BioPark company is developing the candidate to treat a rare neurological disorder.
Feb 2019 · Technical.lyNews article
Gliknik commences dosing in Phase II oral cavity cancer trialclinicaltrialsarena.com/news/newsgliknik-commences-dosing-in-phase-ii-oral-cavity-cancer-trial-5912603/
US-based biopharmaceutical company Gliknik has begun dosing patients in a Phase II clinical trial of biropepimut-S (GL-0817), an immunomodulatory therapeutic intended to prevent recurrence of oral cavity squamous cell cancer.
Aug 2017 · Clinical Trials ArenaNews article
Recombinant IVIG Granted Orphan Drug Designation for CIDPbstquarterly.com/article/recombinant-ivig-granted-orphan-drug-designation-for-cidp/
Pfizer, a licensee of Gliknik Inc., receives U.S. FDA orphan drug designation for GL-2045, its recombinant intravenous immune globulin (IVIG)-mimetic drug, to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
Oct 2015 · BioSupply Trends QuarterlyNews article